Key facts
- This page summarizes Checkmate Strategic Capital 2, LLC's Form 5 filing for QSAM Biosciences, Inc..
- 7 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 20 Feb 2024, 16:51.
Checkmate Strategic Capital 2, LLC - 31 Dec 2023 Form 5 Insider Report for QSAM Biosciences, Inc.
- Reporting relationship
- Other*, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 31 Dec 2023
- Net transaction value
- +$44,998
- Reporting owner signature
- /s/ Checkmate Strategic Capital 2, LLC
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Checkmate Strategic Capital 2, LLC filed Form 5 for QSAM Biosciences, Inc. on 20 Feb 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$44,998.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 5 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QSAM
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $44,998
- Shares
- +8,571
- Change %
- +45%
- Price
- $5.25
- Shares after
- 27,624
- Date
- 19 Dec 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F6
QSAM
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- +69,332
- Change %
- +46%
- Price
- $0.000000
- Shares after
- 220,448
- Date
- 06 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F4
QSAM
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- +65,219
- Change %
- Price
- $0.000000
- Shares after
- 65,219
- Date
- 06 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QSAM
transaction
Derivative
Warrants
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 15 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $6.00
- Footnotes
- F6
QSAM
transaction
Derivative
Warrants
Conversion of derivative security
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,571
- Exercise price
- $5.25
- Footnotes
- F6
QSAM
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -150
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 06 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,219
- Exercise price
- $3.00
- Footnotes
- F7
QSAM
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -156
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 06 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,332
- Exercise price
- $3.00
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Checkmate Strategic Capital 2, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 7 footnotes
Footnote F1
This Form 5 is filed jointly by Charles Thomas Paschall, Checkmate Strategic Capital 2, LLC, Checkmate Capital Group, LLC, and Checkmate Strategic Capital Holdings, LLC (collectively, the "Reporting Persons").
Footnote F2
Each Reporting Person is a member of a Section13(d) group that owns in the aggregate more than 5% of the Issuer's outstanding shares of Common Stock, as disclosed in a Schedule 13D/A, filed on behalf of the Reporting Persons on February 20, 2024. As such, each Reporting Person may be deemed to beneficially own more than 5% of the Issuer's outstanding shares of Common Stock.
Footnote F3
Shares of Common Stock beneficially owned by Checkmate Capital Group, LLC. Mr. Paschall is a member of Checkmate Capital Group, LLC, holding 22.7% of its membership interest, as of February 20, 2024. As such, Mr. Paschall has a proportional pecuniary interest in the shares of Common Stock beneficially owned by Checkmate Capital Group, LLC.
Footnote F4
Shares of Common Stock beneficially owned by Checkmate Strategic Capital 2, LLC. Mr. Paschall is the sole member of Checkmate Strategic Capital 2, LLC as of February 20, 2024. As such, Mr. Paschall has a proportional pecuniary interest in the shares of Common Stock beneficially owned by Checkmate Strategic Capital 2, LLC.
Footnote F5
Shares of Common Stock beneficially owned by Checkmate Strategic Capital Holdings, LLC. Mr. Paschall is the sole member of Checkmate Strategic Capital 2, LLC, which is a controlling member of Checkmate Strategic Capital Holdings, LLC. As such, Mr. Paschall may be deemed to have a pecuniary interest in the Common Stock owned by these entities. Further, Checkmate Capital Group, LLC is a member of Checkmate Strategic Capital Holdings, LLC. As such, Checkmate Capital Group, LLC has a pecuniary interest to the extent of shares of common stock of the Issuer owned by Checkmate Strategic Capital Holdings, LLC.
Footnote F6
On January 15, 2023, the Issuer issued 50,000 warrants to Checkmate Capital Group, LLC for general consulting services at an exercise price of $6.00, which warrants were exercised on a cashless basis at a mutually agreed reduced exercise price of $5.25 per share into 8,571 shares of common stock of the Issuer on December 19, 2023 pursuant to the formula for cashless exercise set forth in a warrant agreement with the Issuer, .
Footnote F7
The Series B Convertible Preferred Stock was convertible into common stock at any time and had no expiration date. Pursuant to an Exchange Agreement signed with the Issuer as of October 17, 2023, the Series B Preferred Stock was automatically exchangeable for common stock of the Issuer at a price of $3.00 per share upon the Issuer listing on Nasdaq or signing an agreement to be acquired, and as a result was exchanged into common stock of the Issuer on February 6, 2024.